Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous XXXX monitoring system.

@entity1 @entity2749 @entity6 @entity2794 @entity413
PURPOSE: The aim of the study was to determine the safety of three intensive insulin therapy methods: @entity2794 ( @entity2794 ), continuous subcutaneous insulin infusion (CSII) and continuous intravenous insulin infusion (IVII) used in poorly controlled type 2 @entity6 @entity1 in hospital condition. The safety of these intensive insulin therapy methods was measured by the assessment of number and duration of symptomatic and symptomfree hypoglycaemic events with use of Continuous @entity413 Monitoring System (CGMS, Medtronic MiniMed). MATERIAL AND METHODS: The study comprised 90 type 2 @entity6 @entity1 treated with conventional insulin therapy based on a twice daily injections with mean @entity413 profile values > 14 mmol/l. The @entity1 were randomized into three groups according to the method of insulin treatment. The first group was treated with @entity2794 , the second group with CSII and the third with IVII. The @entity413 monitoring with the use of CGMS lasted 48 hours and was conducted on the second and on the third day of intensive insulin therapy. @entity413 level below 3.5 mmol/l were recognized as @entity2749 . Intensive insulin treatment was continued until "near normoglycaemia" ( @entity413 levels 4.5-10.0 mmol/l) was achieved and then conventional insulin therapy was readministrated. RESULTS: Mean number of symptomatic hypoglycaemic events detected with CGMS was two times higher for @entity2794 than for IVII (p = 0.04) and for CSII (p = 0.04). Number of symptomfree hypoglycaemic events detected with CGMS was higher for @entity2794 than for IVII and CSII, but the differences were insignificant (NS). Mean duration of one symptomfree hypoglycaemic event detected with CGMS was longer in @entity2794 than in CSII (p = 0.02) and IVII (p = 0.03). It was not observed significant differences in mean duration of one symptomatic @entity2749 between studied groups (NS). CONCLUSIONS: The results of study suggest that CSII and IVII treatment is associated with essentially lower number of symptomatic hypoglycaemic events and shorter mean duration of one symptomfree hypoglycaemic event than @entity2794 .
